ArticleIndian journal of dermatology2013
Fixed-duration therapy in leprosy: limitations and opportunities.
Article in Indian journal of dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Article
- Leprosy research registry a global perspective: Need of hour for a newer vision in India towards zero leprosy.Indian journal of pharmacology · 2025Article
- Efficiency of the Sensory Mapping Score for Hansens's disease diagnosis and follow-up: a functional cure criterion?Frontiers in medicine · 2025Article
- Article
- Role of histopathological, serological and molecular findings for the early diagnosis of treatment failure in leprosy.BMC infectious diseases · 2024Article
- Assessment of Clinical, Histopathological, and Bacteriological Findings in Treated Leprosy Patients with Persistent Skin Lesions: A Retrospective Cohort Study.The American journal of tropical medicine and hygiene · 2023Article
- Natural-Product-Based Solutions for Tropical Infectious Diseases.Clinical microbiology reviews · 2021Review
- Autochthonous North American Leprosy: A Second Case in Canada.Infectious disease reports · 2021Article
- Article
- Putting Crohn's on the MAP: Five Common Questions on the Contribution of Mycobacterium avium subspecies paratuberculosis to the Pathophysiology of Crohn's Disease.Digestive diseases and sciences · 2021Review
- GSMN-ML- a genome scale metabolic network reconstruction of the obligate human pathogen Mycobacterium leprae.PLoS neglected tropical diseases · 2020Article
- Intracellular Mycobacterium leprae Utilizes Host Glucose as a Carbon Source in Schwann Cells.mBio · 2019Article
- Coinfection of leprosy and tuberculosis.BMJ case reports · 2018Article
- Caregivers' views on stigmatization and discrimination of people affected by leprosy in Ghana.PLoS neglected tropical diseases · 2018Article
- Nitazoxanide is active against Mycobacterium leprae.PloS one · 2017Article
- Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy.Risk management and healthcare policy · 2016Review
- The Dermlep Study Part 2: Results of a Nation-Wide Survey of Dermatologists' Access to Quality Leprosy Services at their Clinics and Hospitals in India.Indian dermatology online journalArticle
- The DermLep Study I: Results of Prospective Nation-Wide Survey of the Number & Profile of Leprosy Patients seen by Dermatologists in India.Indian dermatology online journalArticle
- Current Situation of Leprosy in India and its Future Implications.Indian dermatology online journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leprosy has been considered a curable disease after the implementation of multidrug therapy (MDT), which has been proven to be safe and effective, by bringing about a significant change in the global and national scenario of leprosy by upgrading the control of leprosy to the next stage of eradication. Since its introduction, the MDT regimens for the treatment of leprosy have undergone several changes especially with regard to the duration of treatment. The advantages of shortened duration of treatment need to be balanced against the risk of relapse and a lot of controversies exist pertaining to this aspect. The fixed-duration (FD) therapy is not popular among academicians and private practitioners who prefer precise diagnosis and treatment with superior MDT regimens and for a longer duration. On the contrary, from a public health-care point of view, precise diagnosis and a longer treatment schedule are not cost effective and not feasible to be implemented in elimination programs. Hence, a fine balance needs to be maintained between achieving a cure for the patient and protecting the society at risk, and this review discusses the various limitations and opportunities of FD therapy with a note on the newer MDT regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.